Marty Makary

Marty Makary, as the FDA Commissioner, is a key driver behind the new policy to reduce the number of required clinical trials for drug approval. He advocates for slashing bureaucracy and accelerating the availability of new medicines, which could lead to a surge in drug development.

Marty Makary, as the United States===Food and Drug Administration Commissioner, announced the new proposal, emphasizing the agency's priority to remove barriers and encourage scientific advances for rare diseases. His statements highlight the United States===Food and Drug Administration's commitment to regulatory flexibility.

Marty Makary, the FDA Commissioner, announced Vinay Prasad's departure. He has been associated with efforts to make FDA drug reviews faster, but also with some of Prasad's controversial decisions.

Marty Makary, as FDA Commissioner, initially described the approval as a 'significant milestone' and suggested broader potential for Folinic acid in autism, which was later contradicted by the United States===Food and Drug Administration's official stance.

Marty Makary, as United States===Food and Drug Administration Commissioner, has raised concerns about SSRI use during pregnancy, suggesting poor birth outcomes. This could lead to increased caution in prescribing SSRIs to pregnant women.